54 results
Sort by:
-
Quality Use of Diagnostics, Therapeutics and Pathology (QUDTP) Program - Stakeholder Forum
The Department of Health and Aged Care is seeking to engage stakeholders regarding the Quality Use of Diagnostics, Therapeutics and Pathology (QUDTP) Program . The QUDTP provides funding to improve the way medicines and medical tests are prescribed and used. As part of the QUDTP Program, two grant opportunities are delivered: Health Professional Education Grant Program – focusing on educational (academic) activities for... MoreOpened 15 March 2024 -
Public Health (Tobacco and Other Products) Regulations 2023
Supplementary Public Consultation on the Public Health (Tobacco and Other Products) Regulations The Australian Government is undertaking a supplementary public consultation regarding graphic health warnings and health promotion inserts. Updates to these Regulations have been informed from public consultation on the exposure draft released on 31 May 2023 and also includes images of proposed health warnings and health promotion inserts. These Regulations will support the... MoreOpened 11 December 2023 -
Include Mpox Chapter into Australian Immunisation Handbook
The Australian Technical Advisory Group on Immunisation (ATAGI) is consulting with stakeholders to include the monkeypox (mpox) vaccine chapter in the Australian Immunisation Handbook, with an intention to submit the chapter to the National Health and Medical Research Council (NHMRC) for its approval under section 14A of the National Health and Medical Research Council Act 1992. Submission instructions This public consultation will be open for a period of 30 days and you... MoreOpened 1 November 2023 -
Medicare Benefits Schedule Review Advisory Committee Draft Report: Post Implementation Review of Telehealth MBS items
The Medicare Benefits Schedule (MBS) is a list of health professional services (items) that the Australian Government subsidises. MBS items provide patient benefits for a wide range of health services including consultations, diagnostic tests, therapy, and operations. When changes are made to MBS items, a review is undertaken approximately 24 months after to analyse and examine the performance of the changes. This is called a post implementation review. Post... MoreOpened 25 September 2023 -
Modernising My Health Record – Sharing pathology and diagnostic imaging reports by default and removing consumer access delays
In February 2023 the Minister for Health and Aged Care released the Strengthening Medicare Taskforce Report . The report recommended that the government: Modernise My Health Record to significantly increase health information available to consumers and their health care professionals, including by requiring sharing by default for private and public practitioners and services, and make it easier for people and their health care teams to use at the point of care. ... MoreOpened 8 September 2023 -
Shigella SoNG Working Group Survey - Case definitions
Background information from the Shigella SoNG Working Group is required to progress document development that is consistent with the needs of as many jurisdictions as possible. MoreOpened 6 September 2023 -
Feedback on the draft National Microbial Genomics Framework 2024-2025
Microbial genomics is the application of genome sequencing technologies to characterise and analyse pathogens for the purposes of informing clinical and public health investigation and response to communicable disease outbreaks. The implementation of this technology is rapidly transforming the Australian pathology sector and its accelerated implementation to support the COVID-19 response, provides a unique opportunity to leverage its value in understanding and controlling other... MoreOpened 8 August 2023 -
Preparing for, and responding to, future pandemics and other international health emergencies
Australia is participating in two important processes to strengthen the international community’s capacity to prevent, prepare for, and respond to, pandemics and other international health emergencies: the negotiation of a new international legal instrument on pandemic prevention, preparedness and response, and targeted changes to the International Health Regulations (2005) (IHR) through the World Health Organization (WHO). To date, Member States... MoreOpened 7 August 2023 -
Draft National Consumer Engagement Strategy for Health and Wellbeing
A NATIONAL CONSUMER ENGAGEMENT STRATEGY FOR HEALTH AND WELLBEING: This Strategy is designed to strengthen partnerships between health policy makers and the community, as set out in one of the immediate priorities for action under the National Preventive Health Strategy 2021-2030. The purpose of this Strategy is to mobilise a person-centred prevention system by involving communities and consumers in preventive health policy design and implementation in order to enable and support a more... MoreOpened 25 July 2023 -
Proposed Changes to the HPV Vaccine Recommendation
The Australian Technical Advisory Group on Immunisation (ATAGI) is consulting with stakeholders on proposed changes to the human papillomavirus (HPV) vaccination recommendations in the Australian Immunisation Handbook, with an intention to submit the recommendation to the National Health and Medical Research Council (NHMRC) for its approval under section 14A of the National Health and Medical Research Council Act 1992. The draft recommendations and the rationale for the... MoreOpened 20 June 2023 -
Public Health (Tobacco and Other Products) Legislation 2023
We are analysing your feedback Visit this page again soon for the outcomes to this public consultation. Public Consultation on the Exposure Draft On 30 November 2022 the Hon. Mark Butler MP Minister for Health and Aged Care announced tobacco reforms. These reforms bring together current legislation and introduce new measures to reduce tobacco prevalence. The Australian Government is now consulting on the exposure draft legislation for these reforms. The... MoreOpened 31 May 2023 -
Development of the Fourth National Hepatitis B Strategy 2023-2030 and Sixth National Hepatitis C Strategy 2023-2030 - Public Consultation Online Survey
Ensuring Australians can live free from the impact of hepatitis B and hepatitis C is a priority of the Australian Government. We are seeking your feedback on the draft Fourth National Hepatitis B Strategy 2023-2030 and the draft Sixth National Hepatitis C Strategy 2023-2030 (the Strategies). These Strategies are part of the new draft national Blood Borne Viruses (BBV) and Sexually Transmissible Infections (STI) strategies that will build on the... MoreOpened 31 May 2023 -
PHLN HIV Reference Laboratory Survey
PHLN’s recently revised laboratory case definition for HIV has stimulated a review of laboratory algorithms for the confirmation HIV in many primary and reference laboratories around Australia. This presents an opportunity for optimization and standardization of HIV confirmatory testing approaches in Australia. The aim of this survey is to better understand: Current confirmatory testing algorithms used in HIV reference laboratories around Australia. Planned... MoreOpened 28 October 2022 -
Consultation on the revised PBS Post-market Review (PMR) Framework
PBS Post-market Review Framework The Department of Health and Aged Care is inviting stakeholders to provide feedback on a revised draft of the Pharmaceutical Benefits Scheme (PBS) Post-market Review (PMR) Framework. Stakeholders will have the opportunity to engage and provide feedback on the revised draft of the 2022 PMR Framework. The diverse perspectives, experience and knowledge of all stakeholders is highly valued and will contribute to the... MoreOpened 20 October 2022 -
National Health Literacy Strategy Framework Consultation
The National Preventive Health Strategy 2021-2030 outlines Australia’s overarching, long-term approach to prevention. The aim of the National Preventive Health Strategy is to create a sustainable prevention system for all Australians, with a particular focus on the wider determinants of health, reducing health inequity and addressing the increasing burden of disease. This will help all Australians live in good health and wellbeing for as long as possible. The... MoreOpened 12 October 2022 -
CPE scoping survey for Public Health Units
Purpose and Scope The Public Health Laboratory Network (PHLN) Expert Reference Panel (ERP) on Antimicrobial Resistance (AMR) will survey public health laboratories, public health units and other laboratories or teams involved in the testing and reporting of carbapenemase-producing Enterobacterales (CPE). This information will be used for a data-informed analysis, to understand how CPE is detected by testing, reported and actioned in Australia. Key aims The... MoreOpened 26 September 2022 -
CPE scoping survey for Public Health Laboratories and other Laboratories performing surveillance testing for CPE
Purpose and Scope The Public Health Laboratory Network (PHLN) Expert Reference Panel (ERP) on Antimicrobial Resistance (AMR) will survey public health laboratories, public health units and other laboratories or teams involved in the testing and reporting of carbapenemase-producing Enterobacterales (CPE). This information will be used for a data-informed analysis, to understand how CPE is detected by testing, reported and actioned in Australia. Key aims ... MoreOpened 26 September 2022 -
Efficient Funding of Chemotherapy (EFC) Review – Interim Report
The EFC Program provides funding for chemotherapy and other medicines used for the treatment of cancer that are administered through infusion or injection at public or private hospitals. Not all cancer medicines are provided through the EFC Program; some may be subsidised through other sections of the broader Pharmaceutical Benefits Scheme (PBS). The Australian Government is undertaking a review of the EFC Program to examine current EFC arrangements and the associated... MoreOpened 5 September 2022 -
Medicare Benefits Schedule (MBS) Review Advisory Committee - Genetic Counselling Working Group Draft Final Report
The Medicare Benefits Schedule (MBS) is a list of health professional services (items) that the Australian Government subsidises. MBS items provide patient benefits for a wide range of health services including consultations, diagnostic tests, therapy, and operations. In 2021, the Medicare Benefits Scheme (MBS) Continuous Review was established to ensure the MBS continues to support high-quality care, remains flexible, and stays up to date. The MBS Continuous Review involves... MoreOpened 26 August 2022 -
Proposed Changes to the Recommended use of Zoster Vaccines
The Australian Technical Advisory Group on Immunisation (ATAGI) is consulting with stakeholders on proposed changes to the recommended use of Zoster vaccines for inclusion in the Australian Immunisation Handbook, with an intention to submit the recommendation to the National Health and Medical Research Council (NHMRC) for its approval under section 14A of the National Health and Medical Research Council Act 1992. The draft recommendations and the rationale for the changes are outlined in... MoreOpened 8 July 2022 -
Proposed changes to the recommended use of meningococcal B vaccines in people at increased risk of meningococcal B disease
The Australian Technical Advisory Group on Immunisation (ATAGI) is consulting with stakeholders on proposed changes to recommended use of meningococcal B vaccines in people at increased risk of meningococcal B disease for inclusion in the Australian Immunisation Handbook, with an intention to submit the recommendation to the National Health and Medical Research Council (NHMRC) for its approval under section 14A of the National Health and Medical Research Council Act 1992. The draft... MoreOpened 15 June 2022 -
Proposal for a Cost Recovered Pathway for Medical Services Advisory Committee Applications
The Department of Health invites submissions in relation to a proposal to introduce a cost recovered pathway for applications received from commercial entities seeking reimbursement decisions from the Medical Services Advisory Committee (MSAC). This proposal is to introduce a cost recovered pathway for the following application types received, from commercial entities: codependent technologies (medical services and health technologies that... MoreOpened 4 January 2022 -
MDR Shigella - Scoping survey for public health laboratories
This survey seeks to understand how Shigella is being tested for in Australian public health laboratories, and how antibiotic susceptibility testing for multi-drug resistant Shigella is being reported from reference laboratories to public health authorities. The following questions will be used to analyse the testing and reporting processes for MDR Shigella of each jurisdiction. The information provided as part of this survey will be identifiable at the jurisdictional level and... MoreOpened 30 November 2021 -
MDR Shigella - Scoping survey for public health authorities
This survey seeks to understand how Shigella is being tested for in Australia, and how antibiotic susceptibility testing data for multi-drug resistant (MDR) Shigella is being reported to and used by public health authorities. The following questions will be used to analyse the testing and reporting processes for MDR Shigella in each jurisdiction. The information provided as part of this survey will be identifiable at the jurisdictional level and will be used by the Public Health... MoreOpened 30 November 2021 -
Aligning Regulation across Care and Support Sector - Consultation Stage 2
The Australian Government is seeking to align regulation across the aged care, disability support and veterans’ care sectors. The 2021-22 Budget included a range of measures that form a short to longer term program of reform. The Department of Health, the NDIS Quality and Safeguards Commission (NDIS Commission), the Aged Care Quality and Safety Commission (ACQSC), the Department of Social Services (DSS) and the Department of Veterans’ Affairs (DVA) are working together to deliver on... MoreOpened 15 November 2021 -
PHLN COVID-19 Lessons Learned Survey
This survey provides Public Health Laboratory Network (PHLN) members with an opportunity to provide feedback on their experience of the COVID-19 pandemic. The results of this survey will be discussed at the PHLN meeting of 22 November 2021, and will be used to inform the development of the National Public Health Laboratory Strategy. Feedback provided as part of this survey will only be used for the purpose of PHLN discussions and will not be communicated further without expressed... MoreOpened 11 November 2021 -
Consultation Draft - Primary Health Care 10 Year Plan
Future focused primary health care: Australia’s Primary Health Care 10 Year Plan 2022-2032 Consultation Draft - Survey The Consultation Draft of the Primary Health Care 10 Year Plan (the plan) draws on input from consultations with individuals and organisations across the country from late 2019 to mid-2021. The plan represents a high level response to the recommendations of the Primary Health Reform Steering Group (Steering Group) which has been... MoreOpened 13 October 2021 -
Proposed changes to the recommended use of BCG vaccines to prevent tuberculosis
The Australian Technical Advisory Group on Immunisation (ATAGI) is consulting with stakeholders on proposed changes to recommended use of BCG vaccines to prevent tuberculosis for inclusion in the Australian Immunisation Handbook, with an intention to submit the recommendation to the National Health and Medical Research Council (NHMRC) for its approval under section 14A of the National Health and Medical Research Council Act 1992. The draft recommendations and the rationale for the... MoreOpened 6 October 2021 -
MRFF Australian Medical Research and Innovation Strategy and Priorities consultation
The Australian Medical Research and Innovation Strategy (Strategy) is determined by the Australian Medical Research Advisory Board (AMRAB). The current Strategy covers the period 2016-2021, with the next Strategy (2021-2026) to be registered before 8 November 2021. The Medical Research Future Fund Act 2015 (MRFF Act) requires AMRAB to undertake a consultation process before determining a Strategy. The Australian Medical Research and Innovation Priorities ... MoreOpened 20 September 2021 -
Efficient Funding of Chemotherapy (EFC) review
The Efficient Funding of Chemotherapy (EFC) Program provides funding for chemotherapy medicines used for the treatment of cancer that are administered through infusion or injection at public or private hospitals. Not all chemotherapy medicines are provided through the EFC Program, but may be subsidised through the broader Pharmaceutical Benefits Scheme (PBS). In the 2020-21 Budget, the Government announced a review of the current EFC Program. The review will look at the impact... MoreOpened 21 May 2021
54 results.
Page 1 of 2